Arch Biopartners Inc.
ARCH.V
TSX
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 131.85% | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 131.85% | -- | |||
| Cost of Revenue | -74.44% | -17.39% | |||
| Gross Profit | 102.04% | -59.10% | |||
| SG&A Expenses | -0.16% | -6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.54% | -13.21% | |||
| Operating Income | 75.63% | -34.77% | |||
| Income Before Tax | 63.26% | -25.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 63.26% | -25.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 63.26% | -25.22% | |||
| EBIT | 75.63% | -34.77% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 65.41% | -29.13% | |||
| Normalized Basic EPS | 65.06% | -29.69% | |||
| EPS Diluted | 65.41% | -29.13% | |||
| Normalized Diluted EPS | 65.06% | -29.69% | |||
| Average Basic Shares Outstanding | 6.86% | -3.16% | |||
| Average Diluted Shares Outstanding | 6.86% | -3.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
